July 30, 2016
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved Cerdelga (eliglustat) for the long-term treatment of adult patients with the Type 1 form of Gaucher disease, a rare genetic disorder.

Gaucher disease occurs in people who do not produce e"...



VPRIV Patient Information including How Should I Take

What should I discuss with my health care provider before receiving velaglucerase alfa (VPRIV)?

You should not use velaglucerase alfa if you are allergic to it.

FDA pregnancy category B. Velaglucerase alfa is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

It is not known whether velaglucerase alfa passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How is velaglucerase alfa given (VPRIV)?

Velaglucerase alfa is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Velaglucerase alfa must be given slowly, and the IV infusion can take at least 1 hour to complete.

Velaglucerase alfa is usually given every other week. Follow your doctor's dosing instructions very carefully.

Your doctor may occasionally change your dose to make sure you get the best results.

Side Effects Centers

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.